Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
STAAR Surgical Company (NASDAQ: STAA) will release its financial results for Q1 2023 on May 3, 2023, after market close. The company is known for developing implantable lenses to enhance vision and has sold over 2 million ICLs in over 75 countries. A conference call will follow at 4:30 PM Eastern to discuss operational progress and financial outcomes. Interested parties can access the call via phone or the live webcast from STAAR's investor relations website. A replay of the call will be available for a week afterward. With a commitment to ophthalmic surgery for over 40 years, STAAR continues to innovate and expand its reach in the vision correction market.
STAAR Surgical Company (NASDAQ: STAA) announces the appointment of Warren Foust as Chief Operating Officer and Magda Michna, Ph.D., as Chief Clinical, Regulatory and Medical Affairs Officer. This move underscores the company's commitment to growth in the ophthalmic sector. Foust, previously with Johnson & Johnson Vision, brings extensive experience in surgical operations. Michna joins from AcuFocus, Inc., with a strong background in clinical and regulatory affairs. CEO Tom Frinzi emphasizes their roles in expanding the market for EVO ICL lenses.
STAAR Surgical Company (NASDAQ: STAA) reported robust financial results for Q4 and FY 2022, showcasing a strong growth trajectory. Q4 net sales rose to $64.0 million, a 9% increase year-over-year, driven by a 15% rise in ICL sales to $61.2 million. Fiscal 2022 net sales reached $284.4 million, up 23%, with ICL sales soaring 27%. Gross margins improved to 77.7% in Q4 and 78.5% for the year. Net income for Q4 was $5.9 million ($0.12 per share), reflecting a year-over-year increase. Looking ahead, STAAR anticipates approximately $340 million in total ICL sales for FY 2023, representing a 26% growth. The company's cash reserves totaled $225.5 million at year-end.
STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the fourth quarter and fiscal year ending December 30, 2022, on February 21, 2023, after the market closes. A conference call will follow at 4:30 p.m. Eastern to discuss the results. The conference can be accessed via phone or through a live webcast on the company's website. STAAR specializes in designing and manufacturing implantable lenses for ophthalmic surgery, having sold over 2 million ICLs globally.
STAAR Surgical Company (NASDAQ: STAA) has partnered with actress Peyton List to promote its EVO Implantable Collamer® Lenses for myopia correction. List, who underwent the EVO procedure in December 2022, highlights the advantages of not needing contacts or glasses, achieving 20/20 vision post-surgery. The EVO lenses do not remove corneal tissue and have minimal downtime, making them a favorable option compared to LASIK. With myopia's global prevalence projected to reach 50% by 2050, STAAR aims to inspire others to consider EVO for their vision needs.
STAAR Surgical Company reported preliminary sales for Q4 and fiscal 2022, with net sales at approximately